Neurava startup funding profile

Overview

Neurava develops multimodal wearable technology to detect seizures, cardiorespiratory dysfunction, and stratify Sudden Unexpected Death in Epilepsy (SUDEP) risk. Baltimore-based Neurava received a $4M NIH Blueprint MedTech Optimizer award in April 2026 (grant 3U54EB033650-04S5) to develop and validate a quantitative SUDEP risk platform toward first-in-human trials. The company has raised prior venture funding reported above $2M in addition to non-dilutive awards.

Why Neurava is interesting

Wearable epilepsy stack with a $4M NIH Blueprint MedTech Optimizer award (Apr 2026) to build a first-in-class SUDEP risk algorithm — Baltimore HQ at 101 W Dickman St, grant-plus-equity path typical of Hopkins-adjacent device startups.

Product & use cases

Wearable epilepsy monitoring with seizure detection and SUDEP risk stratification roadmap.

• Home and clinical seizure alerting
• SUDEP risk quantification for neurologists and families
• Epilepsy management planning with objective physiologic data

Key facts

• HQ Baltimore, MD (101 W Dickman St)
• NIH Blueprint Optimizer (Apr 2026): $4M for SUDEP risk algorithm
• Multimodal wearable for seizure and cardiorespiratory monitoring
• Prior venture funding $2M+ reported; MedTech Innovator finalist (2023)

Fundraising history

Competitive landscape

Edge: NIH-selected neurotech on mortality outcomes — competes on clinical evidence bar, not consumer wellness UX alone.

• Empatica direct

  Wearable seizure detection incumbent.

• Manual seizure diaries incumbent

  Default workflow; no continuous monitoring.

Industries

Related funding articles

Venture Capital Tracker pieces that cover Neurava's financing or category context.

• Baltimore Startups and VC Firms in 2026: TEDCO, Hopkins Clinical AI, Pearl Diagnostics